Bispecific antibodies/Cancer

特許 権利維持 Cancer immunotherapy with ordinary monoclonal antibodies does not activate T-lymphocytes because this type of cell does not possess Fc receptors, so the Fc region cannot bind to them, and the Fab regions are already used for binding the tumour cells.[7] Bispecific antibodies have a higher cytotoxic potential. They bind to antigens that are expressed relatively weakly.[8] The effective dose is around 0.01 mg·m−2·d−1 (milligrams per square metre body surface area per day), several orders of magnitude lower than with ordinary antibodies.